Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
In this episode of Speaking of Urology®, Amar Kishan, MD, highlights findings from phase 3 MIRAGE trial (NCT04384770), which compared Magnetic Resonance Imaging-guided stereotactic body radiotherapy with Computed Tomography-guided stereotactic body radiotherapy in localized prostate cancer. Kishan is an associate professor of radiation oncology and urology and the chief of genitourinary oncology for radiation oncology at University of California, Los Angeles.
Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.
Microvascular function is lower in Black men after prostate cancer diagnosis
April 8th 2024“Given that non-Hispanic Black men were 4 years younger than the non-Hispanic White men, these data suggest that microvascular dysfunction may appear earlier in non-Hispanic Black men following a prostate cancer diagnosis," says Abigayle B. Simon.